Overview
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Mar 1, 2013 | Series E round | $48M | |
| Sep 21, 2011 | Series E round | $44M | |
| Jul 16, 2008 | Funding round | $14.5M |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 9, 2014 | CardioKinetix Completes $50M Financing | MENLO PARK, CA, Medical device company pioneering a catheter-based treatment for heart failure, announced today that it has completed a $50 million financing. >> Click here for more funding data on CardioKinetix >> To export... |
| Dec 9, 2014 | CardioKinetix Completes $50M Financing | CardioKinetix, Inc., a Menlo Park, Calif.-based medical device company, completed a $50m financing. The round was led by Edwards Lifesciences Corporation, with participation from existing investors U.S. Venture Partners, Tekla Healthcare In... |
| Dec 8, 2014 | CardioKinetix raises $50m, inks buyout deal with Edwards Lifesciences | CardioKinetix said it signed an exclusive option-to-buy agreement with Edwards Lifesciences (NYSE:EW) in connection with a $50 million financing round. The cardiac device company said that Edwards will have the right to purchase CardioKinet... |
| Mar 1, 2013 | CardioKinetix Completes $23M Second Tranche of Series E Financing | CardioKinetix Inc., a Menlo Park, CA-based medical device company developing a catheter-based treatment for heart failure, completed the $23m second-tranche of its Series E financing. This funding, which brings the total amount raised in th... |
| Feb 28, 2013 | CardioKinetix closes $23M tranche in $48M Series E round | CardioKinetix said it’s raised $48 million in its Series E round with the closure of a 2nd tranche worth $23 million and plans to use the proceeds to further its Parachute ventricular partitioning device, which is in a pivotal trial. The Me... |
| Feb 28, 2013 | CardioKinetix Completes $48M in Series E | MENLO PARK, CA, Medical device company pioneering a catheter-based treatment for heart failure, announced today that it has completed the $23 million second-tranche of its Series E financing. >> Click here for more funding data on ... |
| May 9, 2012 | 5 cardiovascular disease medical device companies to watch | “The aging of the population and the near epidemic of obesity and type 2 diabetes even in the younger population will prolong this trend and sustain potential in this market for a long time to come,” said Kenneth Krul, author of a cardiovas... |
| Sep 21, 2011 | CardioKinetix Raises $44M in Series E Financing | CardioKinetix Inc., a Menlo Park, CA-based medical device company that has developed a novel transcatheter implant called the PARACHUTE™ Ventricular Partitioning Device, has raised $44m in a two-tranche Series E financing. The round was led... |
| Sep 21, 2011 | CardioKinetix Pulses To $44M Series E | The financing was led by new investors SV Life Sciences and New Leaf Venture Partners, who joined existing investors, including U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors.... |
Reviews 0
FAQ about Parachute Cardiokinetic
How much funding has Parachute Cardiokinetic raised?
Parachute Cardiokinetic has raised $156.5M in total across 4 funding rounds.
What funding rounds has Parachute Cardiokinetic raised?
Parsers VC lists 4 funding rounds of Parachute Cardiokinetic, among them a Series E round of $48M on Mar 1, 2013, a Series E round of $44M on Sep 21, 2011 and a funding round of $14.5M on Jul 16, 2008.
What has the press written about Parachute Cardiokinetic?
Parsers VC has collected 14 articles mentioning Parachute Cardiokinetic, among them “CardioKinetix Completes $50M Financing” (Dec 9, 2014) and “CardioKinetix Completes $50M Financing” (Dec 9, 2014).
Is Parachute Cardiokinetic still active?
Yes, Parachute Cardiokinetic is active; its latest activity on Parsers VC dates from Dec 10, 2014.